The online version of this article (doi:10.1186/s12890-015-0056-5) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
PLFP, FALM, MAGOR, CISS, and JDR made substantial contributions to the study conception and design, acquisition of data, or analysis and interpretation of data; were involved in drafting the manuscript or revising it critically for important intellectual content; gave final approval of the version to be published; and agree to be accountable for all aspects of the work, ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. CCBA, IAP, and AADCT made substantial contributions to the study conception and design, acquisition of data, or analysis and interpretation of data. LCM was involved in drafting the manuscript and revising it critically for important intellectual content. All authors read and approved the final manuscript.
Exercise has been studied as a prognostic marker for patients with cystic fibrosis (CF), as well as a tool for improving their quality of life and analyzing lung disease. In this context, the aim of the present study was to evaluate and compare variables of lung functioning. Our data included: (i) volumetric capnography (VCAP) parameters: expiratory minute volume (VE), volume of exhaled carbon dioxide (VCO2), VE/VCO2, ratio of dead space to tidal volume (VD/VT), and end-tidal carbon dioxide (PetCO2); (ii) spirometry parameters: forced vital capacity (FVC), percent forced expiratory volume in the first second of the FVC (FEV1%), and FEV1/FVC%; and (iii) cardiorespiratory parameters: heart rate (HR), respiratory rate, oxygen saturation (SpO2), and Borg scale rating at rest and during exercise. The subjects comprised children, adolescents, and young adults aged 6–25 years with CF (CF group [CFG]) and without CF (control group [CG]).
This was a clinical, prospective, controlled study involving 128 male and female patients (64 with CF) of a university hospital. All patients underwent treadmill exercise tests and provided informed consent after study approval by the institutional ethics committee. Linear regression, Kruskal–Wallis test, and Mann–Whitney test were performed to compare the CFG and CG. The α value was set at 0.05.
Patients in the CFG showed significantly different VCAP values and spirometry variables throughout the exercise test. Before, during, and after exercise, several variables were different between the two groups; statistically significant differences were seen in the spirometry parameters, SpO2, HR, VCO2, VE/VCO2, PetCO2, and Borg scale rating. VCAP variables changed at each time point analyzed during the exercise test in both groups.
VCAP can be used to analyze ventilatory parameters during exercise. All cardiorespiratory, spirometry, and VCAP variables differed between patients in the CFG and CG before, during, and after exercise.
Additional file 1: Table S1. Genotypes for the CFTR mutations of patients with cystic fibrosis enrolled in the present study (n = 64).12890_2015_56_MOESM1_ESM.docx
Additional file 2: Table S2. CFTR mutations found in individuals enrolled in the study. Gene and protein localization. Mutation classification and frequency from the present study are designated. Traditional and Human Genome Variation Society standard nomenclature for CFTR mutations are also indicated.12890_2015_56_MOESM2_ESM.docx
Additional file 3: Table S3. Volumetric capnograph markers taking into account groups of patients with cystic fibrosis and healthy subjects. Time points analyzed by groups.12890_2015_56_MOESM3_ESM.docx
Additional file 4: Figure S4. Linear regression of VCO2 and FEV1% by body mass index (BMI). A. Time point 1 - VCO2 by BMI - [Combined: y = 12.382 + 0.031 x (p ≤ 0.001)], [CF: y = 12.381 + 0.025 x (p = 0.001)], [Control: y = 13.810 + 0.029 x (p ≤ 0.001)]. B. Time point 3 - VCO2 by BMI - [Combined: y = 12.573 x + 0.015 (p ≤ 0.001)], [CF: y = 12.278 + 0.013 x (p < 0.001)], [Control: y = 14.244 + 0.013 x (p ≤ 0.001)]. C. Time point 5 - VCO2 by BMI - [Combined: y = 11.854 x + 0.017 (p ≤ 0.001)], [CF: y = 11.712 + 0.015 x (p ≤ 0.001)], [Control: y = 13.266 + 0.016 x (p ≤ 0.001)]. D. Time point 1 - FEV1% by BMI - [Combined: y = 13.566 + 0.056 x (p = 0.001)], [CF: y = 15.127 + 0.023 x (p = 0.196)], [Control: y = 14.919 + 0.049 x (p = 0.133)].12890_2015_56_MOESM4_ESM.pptx
Bernardi DM, Ribeiro AF, Mazzola TN, Vilela MMS, Sgarbieri VC. The impact of cystic fibrosis on the immunologic profile of pediatric patients. J Pediatr. 2013;89 Suppl 1:40–7. CrossRef
Chaves CRMM, Oliveira CQ, Britto JAA, Elsas MICG. Exercise testing, aerobic and strength training for adolescents with cystic fibrosis: a literature review. Rev Bras Saúde Matern Infant. 2007;7 Suppl 3:245–50.
Leeuwen PBVW, Arets HGM, Ent CKV, Beekman JM. Infection, inflammation and exercise in cystic fibrosis. Respir Res. 2013;14:32. CrossRef
Pereira FM, Ribeiro MAGO, Ribeiro AF, Toro AADC, Hessel G, Ribeiro JD. Functional performance on the six-minute walk test in patients with cystic fibrosis. J Bras Pneumol. 2011;37 Suppl 6:735–44. PubMed
Silva OB, Filho DCS. A new proposal to guide velocity and inclination in the ramp protocol for the treadmill ergometer. Arq Bras Cardiol. 2003;81 Suppl 1:42–7.
Wolff G, Brunner JK. Series dead space volume assessed as the mean value of a distribution function. Int J Clin Monit Comp. 1984;1:177–81. CrossRef
Fletcher R, Jonson B. Dead space and the single breath test carbon dioxide during anaesthesia and artificial ventilation. Br J Anasth. 1984;6:109–76. CrossRef
Toulou PP. Distribution of ventilation: clinical evaluation by rapid CO 2 analysis. Chest. 1996;49:139–45.
Smidt U. Emphysema as possible explanation for the alteration of PO 2 and PCO 2 curves. Bull Eur Physiopathol Respir. 1976;12:607–24.
Worth H. Expiratory partial pressure curves in the diagnostic of emphysema. Bull Eur Physiopathol Respir. 1986;22:191–9. PubMed
Ribeiro MA, Silva MT, Ribeiro JD, Moreira MM, Almeida CC, Almeida-Junior AA, et al. Volumetric capnography as a tool to detect early peripheric lung obstruction in cystic fibrosis patients. J Pediatr. 2012;88 Suppl 6:509–17. CrossRef
Ribeiro JD, Ribeiro MAGO, Ribeiro AF. Controversies in cystic fibrosis – from pediatrician to specialist. J Pediatr (Rio J). 2002;78 Suppl 2:S171–86. CrossRef
CFF. Cystic Fibrosis Foundation, Patient Registry 2002 Annual Data Report. Bethesda, Maryland: Patient Registry; 2002.
ATS – American Thoracic Society. ATS Statement: guidelines for the sixminute walk test. Am J Respir Crit Care Med. 2002;166:111–7. CrossRef
Schneiderman-Walker J, Coates AL. Does carbon dioxide retention during exercise predict a more rapid decline in FEV1 in cystic fibrosis? Arch Dis Child. 2005;90 Suppl 8:792–5. PubMed
Fuchs SI, Junge S, Ellemunter H, Ballmann M, Gappa M. Calculation of the capnographic index based on expiratory molar mass-volume-curves-a suitable tool to screen for cystic fibrosis lung disease. J Cyst Fibrosis. 2013;12 Suppl 3:277–83. CrossRef
- Ventilatory abnormalities in patients with cystic fibrosis undergoing the submaximal treadmill exercise test
Paloma Lopes Francisco Parazzi
Fernando Augusto de Lima Marson
Maria Angela Gonçalves de Oliveira Ribeiro
Celize Cruz Bresciani de Almeida
Luiz Cláudio Martins
Ilma Aparecida Paschoal
Adyleia Aparecida Dalbo Contrera Toro
Camila Isabel Santos Schivinski
Jose Dirceu Ribeiro
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II